Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BROLUCIZUMAB vs BROMOCRIPTINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

BROLUCIZUMAB vs BROMOCRIPTINE: Safety Overview

Metric BROLUCIZUMAB BROMOCRIPTINE
Total FAERS Reports 682 864
Deaths Reported 41 75
Death Rate 6.0% 8.7%
Hospitalizations 105 308
Average Patient Age 69.5 yrs 41.4 yrs
% Female Patients 57.1% 57.5%
FDA Approval Date N/A Approved Prior to Jan 1, 1982
Manufacturer Novartis Pharmaceuticals Corporation Zydus Pharmaceuticals USA Inc.
Route INTRAVITREAL ORAL
Marketing Status N/A Prescription